Gail Maderis

Gail has over 20 years of leadership in biopharmaceutical companies, including at Genzyme, where she worked closely with Henri Termeer. In addition to her role as President and CEO of Antiva, she serves on the boards of Valitor, the Biotechnology Innovation Organization (BIO), and the California Life Sciences Institute, and she is a Trustee of the University of California Berkeley Foundation.

Previously, Gail led BayBio, the industry organization representing and supporting Northern California’s life science community. She also previously served as President and CEO of Five Prime Therapeutics, Inc., and held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Gail also practiced management and strategy consulting with Bain & Co. She received a BS in business from UC Berkeley and an MBA from Harvard Business School.